Climb Bio, INC 8-K filings

Climb Bio, Inc. reports that its collaborator, Beijing Mabworks Biotech Co., Ltd., has dosed the first patient in a Phase 2 clinical trial for immunoglobulin A nephropathy in China.

Climb Bio reported Q2 2026 financial results, highlighting progress in its CLYM116 and budoprutug programs, with key data readouts and trial initiations expected, alongside an extended cash runway into late 2028.

Climb Bio, Inc. announced the immediate resignation of director Andrew Levin and the election of Breanna O'Reilly, Ph.D., to its Board of Directors.

Climb Bio, Inc. has entered into a new $100 million at-the-market equity distribution agreement with Jefferies LLC while terminating a previous agreement with Oppenheimer & Co.

Climb Bio announced initial data from its Phase 1b study of budoprutug for primary immune thrombocytopenia (ITP), showing good tolerability and positive platelet responses.

Climb Bio, Inc. held its Annual Meeting of Stockholders on June 5, 2026, where key proposals including amendments to its 2021 Equity Incentive Plan and the election of new directors were approved.

Climb Bio announced favorable initial Phase 1 safety data and translational pharmacometric modeling for its anti-APRIL antibody, CLYM116.

Climb Bio announced first quarter 2026 financial results, highlighting progress in its budoprutug and CLYM116 drug development programs and a $110 million private placement.

Climb Bio, Inc. provided updates on its anti-CD19 monoclonal antibody, budoprutug, highlighting positive subcutaneous formulation data and progress in clinical trials for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.

Climb Bio, Inc. announced a $110 million private placement of common stock and pre-funded warrants to institutional accredited investors.

Climb Bio, Inc. reports the mutual agreement for Senior Vice President, Finance Cindy Driscoll to depart, with CFO Susan Altschuller assuming principal accounting officer duties.

Climb Bio announced its fourth quarter and full year 2025 financial results, highlighting significant progress in its clinical pipeline and a cash runway expected into 2028.

Climb Bio, Inc. announced significant pipeline progress for budoprutug and CLYM116 programs and outlined key anticipated milestones for 2026, alongside a refreshed cash runway into 2028.

Climb Bio, Inc. has filed a lawsuit against Alumis Inc. and its subsidiary Acelyrin, Inc. seeking a declaratory judgment that it does not owe a $3 million milestone payment related to its budoprutug drug candidate.

Climb Bio, Inc. entered an agreement with RA Capital Management, L.P. to exchange 20.44 million common shares for pre-funded warrants, adjusting its capital structure and RA Capital's beneficial ownership.

Climb Bio announced its third-quarter 2025 financial results and provided updates on its budoprutug and CLYM116 clinical programs, alongside leadership team appointments.

Climb Bio, Inc. announced positive long-term follow-up data for its novel anti-CD19 antibody, budoprutug, in primary membranous nephropathy.

Climb Bio, Inc. announced the appointment of Susan Altschuller, Ph.D., MBA, as its new Chief Financial Officer and Treasurer, effective October 1, 2025, alongside an increase in shares reserved for its 2025 Inducement Plan.

Climb Bio, Inc. announced new preclinical data for CLYM116, highlighting its potential as a best-in-class therapeutic for IgA nephropathy with deeper IgA reduction and a longer half-life compared to a first-generation anti-APRIL antibody.

Climb Bio, a clinical-stage biotechnology company, announced its second quarter 2025 financial results and provided updates on its clinical programs for immune-mediated diseases.

Climb Bio, Inc. announced the appointment of Cindy Driscoll as its new Senior Vice President, Finance, and designated her as Principal Financial Officer and Principal Accounting Officer, effective June 17, 2025, following the resignation of Emily Pimblett.

Climb Bio, Inc. announced the successful election of two directors, Judith Dunn, Ph.D. and Stephen Thomas, Ph.D., and the ratification of PricewaterhouseCoopers LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Climb Bio, Inc. announced the mutual separation of its Chief Operating Officer and principal financial officer, Brett Kaplan, M.D., effective May 23, 2025, with current President and CEO Aoife Brennan stepping in as interim principal financial officer.

Climb Bio reports its Q1 2025 financial results, highlighting progress in clinical trials and pipeline development, and anticipates key milestones for its budoprutug and CLYM116 programs.

Climb Bio, Inc. reports the resignation of a director, an upcoming departure, and the appointment of two new directors to its board, effective March 28, 2025.

Climb Bio announces FDA clearance for clinical trials of Budoprutug, pipeline expansion with CLYM116, and a strong financial position with cash runway through 2027.

Climb Bio has entered into a technology transfer and exclusive license agreement with Beijing Mabworks Biotech for the development and commercialization of a proprietary antibody program outside of China, and estimates sufficient cash to fund operations through 2027.

Climb Bio reported its third quarter 2024 financial results, highlighted by FDA clearance for a systemic lupus erythematosus (SLE) trial and the appointment of a new board chair and VP of CMC.

Climb Bio announced its development strategy for budoprutug, an anti-CD19 monoclonal antibody, and provided a corporate update at a virtual investor event.

Eliem Therapeutics, Inc. has officially changed its name to Climb Bio, Inc., effective October 2, 2024, and will begin trading under the new ticker symbol CLYM on Nasdaq starting October 3, 2024.